睿知中国医院研究地图
候选清单

正在招募肺癌乳腺癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors

ClinicalTrials.gov 上登记的一项肺癌和乳腺癌开放试验,由浙江大学医学院附属第二医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方浙江大学医学院附属第二医院Second Affiliated Hospital, Zhejiang University杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07250386,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed advanced, metastatic, or recurrent solid tumors, including non-small cell lung cancer and breast cancer.

    入选标准第 2 条

    CEA positivity confirmed by immunohistochemistry (IHC) in tumor samples within 3 months of screening (clear membrane staining, with positivity rate ≥10%). If the IHC result is more than 3 months old, serum CEA must be above 10 ng/mL.

    入选标准第 4 条

    For patients with malignant pleural effusion, accurate volume assessment of pleural effusion by imaging (CT or MRI) and cytological or thoracoscopic biopsy confirmation of malignant pleural effusion.

    入选标准第 6 条

  3. ECOG performance status of 0-2.

    入选标准第 7 条

  4. Hematology: White blood cell count >2.0×10\^9/L, neutrophils >1.0×10\^9/L, lymphocytes >0.5×10\^9/L, platelets >50×10\^9/L, hemoglobin >80 g/L.

    入选标准第 11 条

    Renal function: Serum creatinine ≤2.0×ULN.

    入选标准第 13 条

    Liver function: ALT and AST ≤3.0×ULN (≤5.0×ULN for those with liver tumor infiltration).

    入选标准第 14 条

    Total bilirubin ≤2.0×ULN.

    入选标准第 15 条

  5. At least one evaluable lesion according to RECIST 1.1, with a longest diameter of ≥10 mm for non-lymph node lesions and a shortest diameter of ≥15 mm for lymph node lesions. Malignant pleural effusion is acceptable for the chest infusion subgroup.

    入选标准第 5 条

  6. History of or concurrent untreated malignancies within 3 years, except for basal cell carcinoma or in situ cervical cancer.

    排除标准第 13 条

    Positive for HBsAg or HBcAb with HBV DNA levels above the normal range, HCV antibody positive with HCV RNA levels above the normal range, HIV antibody positive, or positive for syphilis.

    排除标准第 14 条

  7. Consent to use a reliable and effective method of contraception for 1 year after CAR-T cell infusion (excluding the rhythm method).

    入选标准第 18 条

    Pregnant or breastfeeding women.

    排除标准第 15 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07250386,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Aged 18 years or older, of any gender.
  2. Histologically or cytologically confirmed advanced, metastatic, or recurrent solid tumors, including non-small cell lung cancer and breast cancer.
  3. Disease progression or intolerance after at least second-line standard therapy, including but not limited to surgery, chemotherapy, radiotherapy, targeted therapy, or immunotherapy.
  4. CEA positivity confirmed by immunohistochemistry (IHC) in tumor samples within 3 months of screening (clear membrane staining, with positivity rate ≥10%). If the IHC result is more than 3 months old, serum CEA must be above 10 ng/mL.
  5. At least one evaluable lesion according to RECIST 1.1, with a longest diameter of ≥10 mm for non-lymph node lesions and a shortest diameter of ≥15 mm for lymph node lesions. Malignant pleural effusion is acceptable for the chest infusion subgroup.
  6. For patients with malignant pleural effusion, accurate volume assessment of pleural effusion by imaging (CT or MRI) and cytological or thoracoscopic biopsy confirmation of malignant pleural effusion.
  7. ECOG performance status of 0-2.
  8. Life expectancy of 12 weeks or more.
  9. No serious psychiatric disorders.
  10. The following organ function criteria should be met unless otherwise specified:
  11. Hematology: White blood cell count >2.0×10\^9/L, neutrophils >1.0×10\^9/L, lymphocytes >0.5×10\^9/L, platelets >50×10\^9/L, hemoglobin >80 g/L.
  12. Cardiac function: Echocardiography showing ejection fraction ≥50%, with no significant abnormalities on ECG.
  13. Renal function: Serum creatinine ≤2.0×ULN.
  14. Liver function: ALT and AST ≤3.0×ULN (≤5.0×ULN for those with liver tumor infiltration).
  15. Total bilirubin ≤2.0×ULN.
  16. Oxygen saturation >92% without supplemental oxygen.
  17. Eligible for single or venous blood collection with no contraindications to cell collection.
  18. Consent to use a reliable and effective method of contraception for 1 year after CAR-T cell infusion (excluding the rhythm method).
  19. The participant or their authorized guardian agrees to participate in the clinical trial and signs the informed consent form (ICF), indicating an understanding of the trial's purpose and procedures.

排除标准:Exclusion Criteria:

  1. Clinical symptoms of CNS metastasis or meningeal metastasis at screening, or other evidence suggesting that CNS metastasis or meningeal metastasis is uncontrolled, as determined by the investigator.
  2. Participation in other clinical trials within 4 weeks prior to screening.
  3. Receipt of a live attenuated vaccine within 4 weeks prior to screening.
  4. Receipt of chemotherapy, targeted therapy, or other experimental drugs within 14 days or at least 5 half-lives (whichever is shorter) prior to screening.
  5. Active or uncontrolled infection requiring systemic treatment.
  6. Tumor compression of the trachea or major blood vessels, with significant risk as assessed by the investigator.
  7. History of any of the following cardiac diseases:
  8. New York Heart Association (NYHA) Class III or IV congestive heart failure.
  9. Myocardial infarction or coronary artery bypass grafting (CABG) within 6 months prior to screening.
  10. Clinically significant ventricular arrhythmias or unexplained syncope (except those caused by vasovagal or dehydration).
  11. History of severe non-ischemic cardiomyopathy.
  12. Active autoimmune disease or other conditions requiring long-term immunosuppressive therapy.
  13. History of or concurrent untreated malignancies within 3 years, except for basal cell carcinoma or in situ cervical cancer.
  14. Positive for HBsAg or HBcAb with HBV DNA levels above the normal range, HCV antibody positive with HCV RNA levels above the normal range, HIV antibody positive, or positive for syphilis.
  15. Pregnant or breastfeeding women.
  16. Any other condition that the investigator deems unsuitable for participation in the study.

引自 ClinicalTrials.gov, NCT07250386, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07250386,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07250386